⌘+K

Post-results note

A mixed bag - Q4 review

Kristofer Liljeberg

Elvin Rolder

2026-02-04

06:21 CET

OssDsign delivered a mixed Q4 report with sales 3% below our expectations. The gross margin remained strong, underlying opex was lower than expected and sales commission as a percentage of sales declined Q/Q and Y/Y. On the back of the Q4 report, we lower our 2026–28e sales estimates by 7–10% and our new fair value range is SEK12–18 per share (15–20).

Not quite the acceleration we hoped for. OssDsign’s Q4 report was mixed. Q4 sales at SEK45.1m were 3% below our estimate, though organic sales growth was up 4% Q/Q and 24% Y/Y. Given the mild Q3 and seemingly high activity in the beginning of Q4, we had expected stronger sequential momentum in Q4. According to the company, a slowdown in hiring of salespeople earlier in the year hindered growth in H2 2025, but by the end of Q1 2026, the company expects to have doubled its sales capacity Y/Y. However, there is a lag between when a salesperson joins and when their sales contribution ramps up, thus we believe it could take until the latter part of Q2, or Q3, until there is a tangible pick-up from the new hires. The gross margin was once again strong at 96.3%, and underlying opex (adjusted for CEO transition costs) was lower than anticipated. Furthermore, sales commission and fees as a percentage of sales declined Q/Q and Y/Y to 47.6%.

7–10% cuts to sales. On the back of the Q4 numbers, we lower our 2026–28 sales estimates by 7–10%, of which the underlying component is 2–5% and the rest is due to FX.

New fair value range of SEK12–18 per share. Although we argue the sharp negative reaction to the report was excessive, we acknowledge that continued headwinds from the deteriorating USD and the lag in contribution from the new salesforce could result in a mild start to 2026. The share is now trading at a 2026e EV/sales of 3.2x, >20% below peers. For a re-rating to materialise and the valuation gap towards peers tighten, we believe the Q/Q growth momentum needs to accelerate. We lower our fair value range to SEK12–18 (15–20) per share.

Sweden

Healthcare

Latest share price

SEK

3.2

-4.20%

18 Nov 2026 15:58 CET

Fair value range

SEK

6.0

—

9.0

14 Oct 2026

Market cap

SEK

353

m

Key stats

Year

2026e

EPS

-0.40

EPS (Adj.)

-0.37

Sales Growth

-15.77%

EPS Growth (Adj.)

P/E

P/E (Adj.)

EV/EBITA

-4.7

EV/EBITDA

-4.9

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB